Boston Scientific Co. (NYSE:BSX) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC trimmed its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 1.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 228,981 shares of the medical equipment provider's stock after selling 3,462 shares during the quarter. Yousif Capital Management LLC's holdings in Boston Scientific were worth $23,100,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. TFC Financial Management Inc. raised its stake in Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after buying an additional 210 shares in the last quarter. Colonial Trust Co SC increased its holdings in shares of Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 260 shares during the period. Investment Management Corp VA ADV bought a new position in shares of Boston Scientific in the 4th quarter worth $25,000. Sunbeam Capital Management LLC purchased a new stake in shares of Boston Scientific during the 4th quarter worth $26,000. Finally, Ameriflex Group Inc. bought a new stake in Boston Scientific during the fourth quarter valued at about $31,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

Boston Scientific stock traded down $1.09 during midday trading on Thursday, hitting $98.31. 4,117,996 shares of the company were exchanged, compared to its average volume of 6,506,711. The business has a fifty day simple moving average of $100.70 and a two-hundred day simple moving average of $98.55. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm has a market capitalization of $145.44 billion, a PE ratio of 78.65, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a fifty-two week low of $71.88 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business's revenue was up 20.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.56 EPS. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the sale, the chief executive officer now owns 1,476,882 shares in the company, valued at $153,137,894.58. This trade represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the business's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the sale, the executive vice president now directly owns 178,342 shares of the company's stock, valued at $18,347,824.96. This represents a 24.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 411,970 shares of company stock worth $42,406,693 in the last ninety days. Company insiders own 0.50% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Citigroup reiterated a "buy" rating and issued a $125.00 target price (up from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Needham & Company LLC reiterated a "buy" rating and set a $115.00 price objective on shares of Boston Scientific in a research note on Wednesday, May 28th. Evercore ISI increased their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Barclays lifted their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Finally, Royal Bank of Canada increased their price objective on Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Twenty-one analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $116.00.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.